An update on the pharmaceutical management of thrombosis

References

• Wendelboe AM, Raskob GE. Global burden of thrombosis epidemiologic aspects. Circ Res. 2016;118:1340–1347.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e120S–e151S.
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e24S–e43S.
   PubMedGoogle Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e44S–e88S.
   PubMed Web of Science ®Google Scholar
• Coppens M, Eikelboom JW, Gustafsson D, et al. Translational success stories: development of direct thrombin inhibitors. Circ Res. 2012;111:920–929.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res. 2012;111:1069–1078.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Ageno W, Ansell J, et al. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply. J Thromb Haemost. 2015;13:2132–2133.
   PubMed Web of Science ®Google Scholar
• Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011;130:46–58.
   PubMed Web of Science ®Google Scholar
• Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res. 2012;129:392–400.
   PubMed Web of Science ®Google Scholar
• Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol. 2011;18:349–355.
   PubMed Web of Science ®Google Scholar
• Gailani D, Bane E, Gruber A. Factor XI and contact activation as targets for antithombotic therapy. J Thromb Haemost. 2015;13:1383–1395.
   PubMed Web of Science ®Google Scholar
• Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res. 2016;141(S2):S40–S45.
   Google Scholar
• Seligsohn U. Factor XI deficiency in humans. J Thromb Hemost. 2009;7:84–87.
   Web of Science ®Google Scholar
• Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116:4684–4692.
   PubMed Web of Science ®Google Scholar
• Galson S. The surgeon generals call to action to prevent deep vein thrombosis and pulmonary embolism. US Department of Health and Human Services; 2008. Available from: http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-actionon-dvt-2008.pdf
   Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:381S–453S.
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis,9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e278S–e325S.
   PubMed Web of Science ®Google Scholar
• Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e227S–e277S.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):e195S–e226S.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital VTE prevention. [ cited 2015 Jun]. Available from: https://www.nice.org.uk/guidance/cg92
   Google Scholar
• Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism riskand prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387–394.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e419S–e494S.
   PubMedGoogle Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease chest guideline and expert panel report. Chest. 2016;149:315–352.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7.
   PubMed Web of Science ®Google Scholar
• Ensor J, Riley RD, Moore D, et al. Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. BMJ Open. 2016;6:e011190. doi:10.1136/bmjopen-2016-011190
   PubMed Web of Science ®Google Scholar
• Sindet-Pedersen C, Pallisgaard JL, Olesen JB, et al. Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. Thromb Res. 2015;136:732–738.
   PubMed Web of Science ®Google Scholar
• Chan NC, Eikelboom JW, Weitz JI. Evolving treatments for arterial and venous thrombosis. Role of the direct oral anticoagulant. Circ Res. 2016;118:1409–1424.
   PubMed Web of Science ®Google Scholar
• Comerota AJ, Ramacciotti E. A comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism. Am J Med Sci. 2016;352:92–106.
   PubMed Web of Science ®Google Scholar
• Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11:639–654; Erratum in Nat Rev Cardiol. 2016;13:501.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2016. doi:10.1093/ejcts/ezw313. [Epub ahead of print]
   Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC working group on thrombosis – Task Force on anticoagulants in heart disease. Thromb Haemost. 2016;115:685–711.
   PubMed Web of Science ®Google Scholar
• Cosmi B, Rubboli A, Castelvetri C, et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev. 2001;4:CD002133.
   Google Scholar
• Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;386:281–291.
   PubMed Web of Science ®Google Scholar
• Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016;172:315–336.
   PubMed Web of Science ®Google Scholar
• Helin TA, Lemponen M, Hjemdahl P, et al. From laboratory to clinical practice: dabigatran effects on thrombin generation and coagulation in patient samples. Thromb Res. 2015;136:154–160.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab. The antidote for reversal of dabigatran. Circulation. 2015;132:2412–2422.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Cabral KP. Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013;36:133–140.
   PubMed Web of Science ®Google Scholar
• Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24–S33.
   PubMed Web of Science ®Google Scholar
• Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–351.
   PubMed Web of Science ®Google Scholar
• Samama MM, Amiral J, Guinet C, et al. Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev Hematol. 2013;6:155–164.
   PubMed Web of Science ®Google Scholar
• Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;17(12):35–44.
   Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–2424.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31–39.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–2786.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–2775.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009;373:1673–1680.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009;91:636–644.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594–604.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–815.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–2498.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–2185.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double- blind, non-inferiority trial. Lancet. 2007;370:949–956.
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721–729.
   PubMed Web of Science ®Google Scholar
• Fuji T, Wang CJ, Fujita S, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014;134:1198–1204.
   PubMed Web of Science ®Google Scholar
• Fuji T, Fujita S, Kawai Y, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty:STARS J-V. Thromb J. 2015;13:27.
   PubMed Web of Science ®Google Scholar
• Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.
   PubMed Web of Science ®Google Scholar
• Riva N, Dentali F, Permunian ET, et al. Major bleeding and case fatality rate with the direct oral anticoagulants in orthopedic surgery: a systematic review and meta-analysis. Semin Thromb Hemost. 2016;42:42–54.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. MAGELLAN Investigators. N Engl J Med. 2013;368:513–523.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–2177.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al.; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–544.
   Web of Science ®Google Scholar
• ENSTEIN- DVT and EXTENSION Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510.
   PubMed Web of Science ®Google Scholar
• EINSTEIN-PE Investigators. Oral rivaroxaban for symptomatic pulmonary embolism. N Engl J Med. 2012 March. doi:10.1056/nejmoa1113572
   Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. AMPLIFY-EXT Investigators. N Engl J Med. 2013;368(8):699–708.
   PubMed Web of Science ®Google Scholar
• Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Hokusai-VTE Investigators. N Engl J Med. 2013;369:1406–1415.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–2352.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.; RE-COVER II Trial Investigators. Circulation. 2014;129:764–772.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. N Engl J Med. 2013;368:709–718.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Lane DA. Stroke prevention in atrial fibrillation. A systematic review. JAMA. 2015;313:1950–1962.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF Edoxaban versus warfarin in patients with atrial fibrillation. ENGAGE AF-TIMI 48 Investigators. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary sindrome. N Engl J Med. 2011;365:699–708.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
   PubMed Web of Science ®Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis.; FXI-ASO TKA Investigators. N Engl J Med. 2015;372:232–240.
   PubMed Web of Science ®Google Scholar
• Whitlock RP, Whitlock R, Fordyce CB, et al. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC trial. Thromb Haemost. 2016;12:116. [Epub ahead of print].
   Google Scholar
• Sox HC, Greenfield S. Comparative effectiveness research: a report from the institute of a report from the Institute of Medicine. Ann Intern Med. 2009;151:203–205.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857. doi:10.1136/bmj.h1857
   PubMed Web of Science ®Google Scholar
• Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. Thromb Haemost. 2013;110:205–212.
   PubMed Web of Science ®Google Scholar
• Björck F, Sandén P, Renlund H, et al. Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res. 2015;136:216–220.
   PubMed Web of Science ®Google Scholar
• Sjögren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–1377.
   PubMed Web of Science ®Google Scholar
• Björck F, Renlund H, Lip GY, et al. Outcomes in a Warfarin-treated population with atrial fibrillation. JAMA Cardiol. 2016;1:172–180.
   PubMedGoogle Scholar
• Reiffel JA, Weitz JI, Reilly P, et al.; on behalf of the other Cardiac Safety Research Consortium presenters and participants. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: a cardiac safety research consortium think tank. Am Heart J. 2016;177:74–86.
   PubMed Web of Science ®Google Scholar
• Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement ofthe anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128–1139.
   PubMed Web of Science ®Google Scholar
• Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39:395–402.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Thiele T, Selling K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113:931–942.
   PubMed Web of Science ®Google Scholar
• Cohen D. Concerns over data in key dabigatran trial. BMJ. 2014;349:g4747. doi:10.1136/bmj.g4747
   Google Scholar
• Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014;349:g4681. doi:10.1136/bmj.g4681
   PubMed Web of Science ®Google Scholar
• Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670. doi:10.1136/bmj.g4670
   PubMed Web of Science ®Google Scholar
• Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517. doi:10.1136/bmj.g4517
   PubMed Web of Science ®Google Scholar
• Siegal DM, Cuker A. Reversal of target-specific oral anticoagulants. Drug Discov Today. 2014;19:1465–1470.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Förster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955–962.
   PubMed Web of Science ®Google Scholar
• Raccah BH, Perlman A, Danenberg HD, et al. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials. Chest. 2016;149:1516–1524.
   PubMed Web of Science ®Google Scholar
• Obamiro KO, Chalmers L, Bereznicki LR. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 2016;16:349–363.
   PubMed Web of Science ®Google Scholar
• Castellucci LA, Shaw J, van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale. Thromb Res. 2015;136:727–731.
   PubMed Web of Science ®Google Scholar
• Stone JA, Earl KM, O’Neill BJ, et al. Aligning health care policy with evidence-based medicine: the case for funding direct oral anticoagulants in atrial fibrillation. Can J Cardiol. 2014;30:1245–1248.
   PubMed Web of Science ®Google Scholar
• Jaffer IH, Fredenburgh JC, Hirsh J, et al. Medical device-induced thrombosis: what causes it and how can we prevent it? J Thromb Haemost. 2015;13:S72–S81.
   PubMed Web of Science ®Google Scholar